Skip to main content

Table 3 Description of patient ascites samples used for quantitative Real-Time PCR analysis

From: A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer

Sample no. Diagnosis Silverberg grade FIGO stage Treatment Age Survival
Chemonaive       
1 Serous Cystadenoma/ Early Serous Borderline NA NA None 64 NA
2 Serous Cystadenocarcinoma NA III None 65 1 year 5 monthsa
3 Serous Papillary Carcinoma G3 NA None NA NA
4 Papillary Serous Cystadenocarcinoma G3 IIIc None 48 1 year 6 monthsa
5 Serous Cystadenocarcinoma NOS G3 IIIa None 51 1 year 3 monthsa
6 Serous Cystadenocarcinoma NOS G3 NA None 71 1 year 1 montha
Recurrent       
1 Serous Cystadenocarcinoma NOS G3 IIc Carboplatin and Paclitaxel 2 Cycles 64 5 months until death
2 Adenocarcinoma NOS NA IV Carboplatin and Paclitaxel 6 Cycles 67 2 years 8 months until death
3 Serous Cystadenocarcinoma NOS G3 IIIc Carboplatin/Paclitaxel/ Bevacizumab-VGEF Inhibitor (ICON7 Trial) 18 Cycles 55 5 years 6 months until death
4 Papillary Serous Cystadenocarcinoma G3 IIIc Carboplatin and Paclitaxel 6 Cycles 59 3 years 2 months until death
Gemicitabine and Cisplatin
5 Papillary Serous Cystadenocarcinoma G3 IIIc Carboplatin/Paclitaxel/BIBF1120- Angiogenesis Inhibitor (OVAR12 Study) 46 3 years 11 months ALC
6 Serous Cystadenocarcinoma NOS G3 IV Bevacizumab 1 cycle 57 4 years 3 months
Paclitaxel and Cisplatin 6 cycles   ALC
Doxorubicin Pegylated Liposomal 6 cycles
  1. NOS Not Otherwise Specified, ALC At Last Contact
  2. aindicates patients were alive at the time of manuscript preparation